Complex Formation Equilibria and Molecular Structure of Divalent Metal Ions–Vitamin B3–Glycine Oligopeptides Systems

被引:0
作者
Aisha Y. Rajhi
Yi-Hsu Ju
Artik E. Angkawijaya
Ahmed E. Fazary
机构
[1] King Khalid University,Chemistry Department, Faculty of Science
[2] National Taiwan University of Science and Technology,Department of Chemical Engineering
[3] Egyptian Organization for Biological Products and Vaccines (VACSERA Holding Company),Applied Research Sector
来源
Journal of Solution Chemistry | 2013年 / 42卷
关键词
Niacin; Potentiometry; Spectrophotometry; Cyclic voltammetery; Conductometry; Gaussian 09;
D O I
暂无
中图分类号
学科分类号
摘要
Complex formation of divalent transition metal ions (copper(II), cobalt(II) and nickel(II)), vitamin B3 (nicotinic acid) and glycine oligopeptides (glycine, glycylglycine, glycyl-l-phenylalanine, and glycylglycylglycine) were studied at 298 K in aqueous solutions using the pH-potentiometric technique. The copper Cu(II), cobalt Co(II), and nickel Ni(II) complexing capacity of vitamin B3 in the absence and in the presence of glycine peptides and their overall stability constants in aqueous solutions were obtained and explained by the HYPERQUAD 2008 program using the potentiometric data. From the protonation and complex formation constants, representative complex species distribution diagrams were obtained using HYSS 2009 software. The UV–Vis spectroscopic, cyclic voltammeteric and conductometric titration measurements were carried out to give qualitative information about the conformation of the complexes formed in these solutions and their stoichiometric ratios. The Gibbs energies and the molecular structures of the complexes were evaluated and predicted using Gaussian 09 software molecular modeling and density functional theory calculations.
引用
收藏
页码:2409 / 2442
页数:33
相关论文
共 180 条
  • [1] Jacobson EL(2012)Niacin: vitamin and antidyslipidemic drug Subcell. Biochem. 56 37-47
  • [2] Kim H(2005)Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review J. Intern. Med. 258 94-114
  • [3] Kim M(2010)Energetics and structure of nicotinic acid (niacin) J. Phys. Chem. B 114 5475-5485
  • [4] Jacobson MK(2006)The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic agent Trends Pharmacol. Sci. 27 384-390
  • [5] Carlson LA(2001)Characterization of a G-protein coupled receptor for nicotinic acid Mol. Pharmacol. 59 349-357
  • [6] Gonçalves EM(2012)Niacin: the evidence, clinical use, and future directions Curr. Atheroscler. Rep. 14 49-59
  • [7] Bernardes CES(2003)Molecular identification of high and low affinity receptors for nicotinic acid J. Biol. Chem. 278 9869-9874
  • [8] Diogo HP(2008)Effects of laropiprant on nicotinic acid induced flushing in patients with dyslipidemia Am. J. Cardiol. 101 625-630
  • [9] Minas da Piedade ME(2001)Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol Arterioscler. Thromb. Vasc. Biol. 21 1783-1789
  • [10] Offermanns S(2001)Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease New. Engl. J. Med. 345 1583-1592